Search results for: rare disease

Reforming Health Technology Assessments to Embrace...

The advent of cell and gene therapies (CGTs) represents a paradigm shift in medicine, offering the p...

Read more
World EPA 2025 Summary

We were thrilled to attend the World Evidence, Pricing and Access Congress (World EPA) in Amsterdam ...

Read more
Pricing and Market Access trends: 2025

Our review of the 2024 pricing and market access revealed key challenges facing the pharmaceutical i...

Read more
A 2024 update: Is NRDL inclusion in China really t...

The National Healthcare Security Administration (NHSA) of China completed its annual review of the N...

Read more
WODC Europe 2024: Are NICE Achieving Their Timelin...

AUTHORS: Amrit Kaliasethi, Tia Kwong, Mariam Bibi OBJECTIVES  In 2013, England’s National Ins...

Read more
Strategic approaches to achieving HTA approval for...

Achieving HTA approval for orphan drugs requires strategic planning, early engagement, strong eviden...

Read more
World Orphan Drug Congress Europe 2024

We're thrilled to announce our participation at World Orphan Drug Congress Europe 2024 in Barcelona ...

Read more
How will recent safety signals impact patient acce...

Safety signals have sparked vital discussions on patient access to ATMPs, marking a pivotal moment i...

Read more
World EPA Congress 2024

The World Evidence, Pricing, and Access (EPA) Congress stands as Europe’s premier event in mar...

Read more
Financing of new orphan drugs in Spain increases i...

Spain seeks to enhance financing for orphan drug access, signalling a push for better timelines and ...

Read more
Older
Newer

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.

Talk to an expert

Remap Consulting have significant experience working with pharmaceutical and biotech companies in helping them navigate global market access.​

Get in touch